Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
59.6M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
42.3M
-
Shares change
-
+8.76M
-
Total reported value, excl. options
-
$1.59B
-
Value change
-
+$332M
-
Put/Call ratio
-
1.75
-
Number of buys
-
82
-
Number of sells
-
-34
-
Price
-
$37.65
Significant Holders of Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share (JANX) as of Q1 2024
129 filings reported holding JANX - Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q1 2024.
Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share (JANX) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.3M shares
of 59.6M outstanding shares and own 71% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (9.17M shares), FMR LLC (7.75M shares), ORBIMED ADVISORS LLC (4.28M shares), BVF INC/IL (2.92M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.78M shares), CITADEL ADVISORS LLC (2.35M shares), JANUS HENDERSON GROUP PLC (1.97M shares), BlackRock Inc. (1.69M shares), VANGUARD GROUP INC (1.36M shares), and RTW INVESTMENTS, LP (1M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.